Followers | 2775 |
Posts | 77901 |
Boards Moderated | 1 |
Alias Born | 05/10/2007 |
Tuesday, March 08, 2016 5:35:15 PM
PALATINE, IL--(Marketwired - March 08, 2016) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, today announced that Bob Jones, President and Chief Executive Officer, will present at the 28(th) Annual ROTH Capital Conference on Monday, March 14, 2016 at 11:30 a.m. Pacific Time. The conference is being held at the Ritz-Carlton Laguna Niguel in Dana Point, California.
The presentation will be webcast live and may be accessed by visiting Acura's website at www.acurapharm.com. A replay of the webcast will be available for 90 days.
Recent ACUR News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 03:53:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 03:27:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 10:13:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 08:23:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 08:23:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 08:20:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 08:20:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 05:01:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/06/2023 07:35:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/20/2023 05:08:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/20/2023 05:08:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/20/2023 05:07:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/20/2023 05:07:02 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/03/2023 04:42:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 04:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/25/2023 08:10:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 11:00:22 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/31/2023 08:10:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/30/2023 08:10:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2023 03:20:22 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/10/2023 04:17:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/28/2023 08:41:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/28/2023 03:50:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/13/2023 01:00:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2023 06:04:11 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM